Your browser is no longer supported. Please, upgrade your browser.
AVGR Avinger, Inc. daily Stock Chart
Avinger, Inc.
Index- P/E- EPS (ttm)-2.61 Insider Own0.30% Shs Outstand51.34M Perf Week19.82%
Market Cap29.15M Forward P/E- EPS next Y-0.49 Insider Trans0.00% Shs Float31.25M Perf Month49.73%
Income-23.90M PEG- EPS next Q-0.17 Inst Own8.50% Short Float1.80% Perf Quarter70.32%
Sales9.60M P/S3.04 EPS this Y90.50% Inst Trans-0.21% Short Ratio0.09 Perf Half Y-14.33%
Book/sh0.30 P/B1.73 EPS next Y46.80% ROA-89.00% Target Price- Perf Year-63.89%
Cash/sh0.18 P/C2.94 EPS next 5Y- ROE-307.30% 52W Range0.24 - 1.98 Perf YTD-54.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.90% Beta1.46
Dividend %- Quick Ratio0.80 Sales past 5Y-4.00% Gross Margin31.40% 52W Low130.78% ATR0.06
Employees81 Current Ratio1.10 Sales Q/Q27.80% Oper. Margin- RSI (14)59.34 Volatility20.74% 12.72%
OptionableNo Debt/Eq2.14 EPS Q/Q66.70% Profit Margin- Rel Volume4.16 Prev Close0.52
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume6.23M Price0.56
Recom2.50 SMA2035.11% SMA5039.53% SMA200-20.58% Volume22,806,494 Change7.00%
Mar-09-18Initiated Ladenburg Thalmann Buy
Apr-12-17Downgrade Oppenheimer Outperform → Perform
Apr-11-17Downgrade Canaccord Genuity Buy → Hold $4.30 → $1
Dec-29-15Downgrade Dougherty & Company Buy → Neutral
May-08-15Reiterated Dougherty & Company Buy $16 → $18
Apr-29-15Initiated Dougherty & Company Buy $16
Feb-24-15Initiated Oppenheimer Outperform $15
Feb-24-15Initiated Canaccord Genuity Buy $18
Aug-06-20 12:30PM  
Aug-04-20 12:00PM  
Aug-03-20 08:05PM  
Jul-30-20 04:01PM  
Jul-27-20 08:30AM  
Jul-09-20 11:50AM  
Jun-30-20 08:03PM  
Jun-29-20 12:15PM  
Jun-26-20 02:20PM  
Jun-23-20 08:40PM  
Jun-10-20 07:52AM  
May-29-20 12:42PM  
May-28-20 12:00PM  
May-26-20 11:54AM  
May-20-20 08:30AM  
May-13-20 04:01PM  
May-07-20 09:00AM  
May-06-20 12:00PM  
Apr-30-20 11:17AM  
Apr-27-20 09:25PM  
Apr-17-20 12:00PM  
Apr-15-20 09:00AM  
Mar-13-20 11:17AM  
Mar-05-20 04:05PM  
Feb-27-20 08:00AM  
Feb-25-20 08:30AM  
Feb-04-20 08:00AM  
Jan-31-20 04:01PM  
Jan-30-20 08:30AM  
Jan-28-20 08:05PM  
Jan-23-20 08:00AM  
Jan-19-20 07:42AM  
Jan-09-20 08:30AM  
Dec-17-19 08:30AM  
Dec-16-19 08:30AM  
Nov-21-19 09:43AM  
Nov-18-19 09:18AM  
Nov-15-19 07:06AM  
Nov-05-19 04:01PM  
Oct-31-19 06:52AM  
Oct-29-19 09:00AM  
Oct-24-19 09:00AM  
Oct-18-19 10:23AM  
Oct-17-19 07:27AM  
Oct-09-19 08:00AM  
Sep-18-19 08:00AM  
Sep-17-19 08:00AM  
Sep-10-19 08:00AM  
Sep-04-19 08:30AM  
Aug-29-19 08:00AM  
Aug-26-19 04:02PM  
Aug-21-19 09:00PM  
Aug-19-19 07:00AM  
Aug-06-19 06:24PM  
Jul-31-19 04:01PM  
Jul-29-19 08:00AM  
Jul-26-19 09:00AM  
Jul-16-19 08:00AM  
Jul-10-19 09:40AM  
Jul-08-19 07:30AM  
Jun-21-19 04:05PM  
Jun-04-19 07:00AM  
May-30-19 04:00PM  
May-24-19 09:30AM  
May-16-19 07:30AM  
May-14-19 10:10AM  
May-08-19 05:28PM  
May-03-19 09:30AM  
May-02-19 05:45PM  
Apr-17-19 08:00AM  
Apr-15-19 08:00AM  
Apr-11-19 09:39AM  
Apr-10-19 08:39AM  
Apr-09-19 08:14AM  
Mar-27-19 08:00AM  
Mar-12-19 11:34PM  
Mar-06-19 04:05PM  
Mar-01-19 08:30AM  
Feb-28-19 08:30AM  
Jan-28-19 08:00AM  
Jan-16-19 10:16AM  
Jan-15-19 06:23AM  
Dec-28-18 07:06AM  
Dec-21-18 10:39AM  
Dec-19-18 06:00AM  
Dec-13-18 07:00AM  
Dec-06-18 09:15AM  
Nov-29-18 08:06AM  
Nov-28-18 07:04AM  
Nov-21-18 08:50AM  
Nov-15-18 08:55AM  
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.